CAMARILLO, Calif.–(BUSINESS WIRE)–Dyve Biosciences, Inc. (“Dyve”), a clinical-stage platform biotechnology company with assets in immunology and oncology, today announced that Tatyana Beldock has joined Dyve’s Board of Directors.
Ryan Beal, M.D., Chief Executive Officer of Dyve, stated: “We are thrilled to have Tatyana join our Board. Tatyana brings a wealth of business, investment, and strategic experience to our team. I look forward to working side-by-side with her as we advance our immunology and oncology assets through the clinics and expand our strategic partnerships.”
Tatyana Beldock has over 25 years of operating and financial experience in healthcare, strategically fueling company growth, advancing technology, and increasing shareholder value for companies ranging from Fortune 100s, Johnson & Johnson, Pfizer, J.P. Morgan, and Citigroup to startups (as a founder & CEO, board member, venture capitalist, and advisor). Her track record includes delivering multi-billion-dollar outcomes in highly competitive markets and more than thirty transactions exceeding $24 billion in value across biopharmaceuticals, health technology, medical devices, and financials. She is currently Founder and Managing Partner at FireRock Advisors.
“Joining the Dyve Board of Directors is a wonderful opportunity to contribute to developing multiple breakthrough therapies for patients. Dyve’s platform science has shown tremendous potential in treating immuno-inflammatory and oncologic diseases. I’m excited to join the talented group of Dyve board directors and participate in this important work,” said Ms. Beldock.
Ms. Beldock holds an MBA from Harvard Business School and a B.S. with Honors from Carnegie Mellon University.
About Dyve Biosciences
Dyve Biosciences (“Dyve”) is a clinically validated biotech that is breaking barriers to deliver on the promise of pH modulation. Decades of published research demonstrate that neutralizing microenvironment acidity profoundly impacts disease, with multi-fold improvements in tumor metastases, cancer survival, and immune response. Leveraging our groundbreaking DMAX delivery platform, Dyve’s science directly targets the acidic microenvironments that drive cancer cell growth and inflammation. Dyve has demonstrated that it can deliver intuitive, targeted pH modulation to treat oncologic and immuno-inflammatory diseases. Learn more at www.dyvebio.com.
Contacts
Corporate & Investor Contact
Jim McGee
Dyve Biosciences, Inc.
833-398-3246
jim.mcgee@dyvebio.com